Symptomatic Lactic Acidosis in Hospitalized Antiretroviral-Treated Patients with Human Immunodeficiency Virus Infection: A Report of 12 Cases
- Circulating p24 Antigen Levels and Responses to Dideoxycytidine in Human Immunodeficiency Virus (HIV) Infections. Merigan, Thomas C.; Skowron, Gail; Bozzette, Samuel A.; Richman, Douglas; Uttamchandani, Raj; Fischl, Margaret; Schooley, Robert; Birsch, Martin; Soo, Whaijen; Pettinelli, Carla; Schaumburg, Herbert // Annals of Internal Medicine;2/1/89, Vol. 110 Issue 3, p189
Presents a study that determined the safety and efficacy of dideoxycytidine in HIV infections. Design of the study; Setting of the study; Profile of patients; Intervention given on the the patients; Analysis on the data; Discussion on the results.
- Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study. Boubaker, K.; Flepp, M.; Sudre, P.; Furrer, H.; Haensel, A.; Hirschel, B.; Boggian, K.; Chave, J.P.; Bernasconi, E.; Egger, M.; Opravil, M.; Rickenbach, M.; Francioli, P.; Telenti, A. // Clinical Infectious Diseases;12/1/2001, Vol. 33 Issue 11, p1931
The prevalence, clinical presentation, and risk factors for hyperlactatemia among patients receiving antire-troviral therapy was determined during a 1-month period for patients in the Swiss HIV Cohort Study. Overall, 73 (8.3%) of 880 patients presented an increase in serum lactate of 1 1.1...
- Human Immunodeficiency Virus Type 1 Quasi Species That Rebound after Discontinuation of Highly Active Antiretroviral Therapy Are Similar to the Viral Quasi Species Present before Initiation of Therapy. Imamichi, Hiromi; Crandall, Keith A.; Natarajan, Ven; Jiang, Min Kang; Dewar, Robin L.; Berg, Steve; Gaddam, Arunasri; Bosche, Marjorie; Metcalf, Julia A.; Davey Jr., Richard T.; Lane, H. Clifford // Journal of Infectious Diseases;1/1/2001, Vol. 183 Issue 1, p36
Presents a study which conducted an HIV quasi species analysis for patients with HIV RNA to identify the source of the viruses that emerge after discontinuation of therapy. Methods; Results; Discussion.
- Battle Fatigue. // Pharmaceutical Executive;Apr2001, Vol. 21 Issue 4, p179
Discusses the findings of a survey among HIV-positive individuals about complying with their treatment regimens. Percentage of respondents who find it difficult to adhere to their prescribed treatment; Obstacles to compliance; Features of HIV/AIDS treatment plans; Things that could simplify...
- A Prospective Study of Predictors of Adherence to Combination Antiretroviral Medication. Golin, Carol E.; Liu, Honghu; Hays, Ron D.; Miller, Loren G.; Beck, C. Keith; Ickovics, Jeanette; Kaplan, Andrew H.; Wenger, Neil S. // JGIM: Journal of General Internal Medicine;Oct2002, Vol. 17 Issue 10, p756
OBJECTIVE: Adherence to complex antiretroviral therapy (ART) is critical for HIV treatment but difficult to achieve. The development of interventions to improve adherence requires detailed information regarding barriers to adherence. However, short follow-up and inadequate adherence measures...
- Once-Daily Combination Therapy with Emtricitabine, Didanosine, and Efavirenz in Human Immunodeficiency Virus-Infected Patients. Molina, Jean-Michael; Ferchal, Francoise; Rancinan, Corinne; Raffi, Francois; Rozenbaum, Willy; Sereni, Daniel; Morlat, Philippe; Journot, Valerie; Decazes, Jean-Marie; Chene, Genevieve // Journal of Infectious Diseases;8/1/2000, Vol. 182 Issue 2
Examines the safety and efficacy of once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus (HIV)-infected patients. Management of HIV infection through highly active antiretroviral therapy (HAART); Analysis on the treatment-related adverse...
- Is gene therapy a good therapeutic approach for HIV-positive patients? Marathe, Jai G.; Wooley, Dawn P. // Genetic Vaccines & Therapy;2007, Vol. 5, p1
Despite advances and options available in gene therapy for HIV-1 infection, its application in the clinical setting has been challenging. Although published data from HIV-1 clinical trials show safety and proof of principle for gene therapy, positive clinical outcomes for infected patients have...
- Ritonavir may be linked to liver damage in people with hepatitis and HIV. // Infectious Disease News;Nov2008, Vol. 21 Issue 11, p20
The article reports that Ritonavir may be linked to liver damage in people with hepatitis and HIV. Research indicate that patients coinfected with hepatitis and HIV receiving ritonavir produced low levels of the liver enzyme, CYP3A4. A study conducted by Tufts University School of Medicine in...
- Long-Term Clinical Outcome of HIV-Infected Patients with Discordant Immunologic and Virologic Responses to a Protease Inhibitor-Containing Regimen. Piketty, Christophe; Weiss, Laurence; Thomas, Francois; Mohamed, Ali Si; Belec, Laurent; Kazatchkine, Michel D. // Journal of Infectious Diseases;5/1/2001, Vol. 183 Issue 9, p1328
Presents a study which examined the long-term clinical, virologic and immunologic outcomes of HIV-infected patients who are on a protease inhibitor regimen of antiretroviral therapy. Methodology; Results; Discussion.